Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s Disease

Glial cell line-derived neurotrophic factor (GDNF) has been shown to exert neuroprotective effects on dopamine (DA) neurons in vivo. Here we report long-term rescue of nigral DA neurons after delayed short-term GDNF administration in a rat lesion model that reproduces the slowly progressing degenerative process seen in Parkinson’s disease. GDNF injected close to the substantia nigra provided near-complete protection and persistent survival of the lesioned nigral neurons for at least 4 months after discontinuation of GDNF treatment. Long-term rescue of the nigral cells, however, was not accompanied by any significant reinnervation of the lesioned striatal target or any signs of functional recovery in either drug-induced or spontaneous motor behaviors. We conclude that not only preservation of the nigral DA neurons but also restoration of striatal DA function is necessary for functional recovery in the rat Parkinson model.

• Publication year

  1996

• Venue

  Journal of Neuroscience

• Publication date

  1996-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1523/JNEUROSCI.16-22-07206.1996PMID 8929429PMCID PMC6578933
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat.

  1996cited by this paper
• GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice

  1996cited by this paper
• Functional recovery in parkinsonian monkeys treated with GDNF

  1996cited by this paper
• Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain

  1995cited by this paper
• Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

  1995influential reference
• Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.

  1995cited by this paper
• GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

  1995influential reference
• Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo

  1995cited by this paper
• Glial cell line‐derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons

  1995influential reference
• Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.

  1995cited by this paper
• Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test

  1995cited by this paper
• Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo

  1994cited by this paper
• Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model

  1994cited by this paper
• Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

  1994cited by this paper
• The role of positron emission tomography in the assessment of human neurotransplantation.

  1993influential reference
• c-jun expression in substantia nigra neurons following striatal 6-hydroxydopamine lesions in the rat.

  1993cited by this paper
• GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

  1993cited by this paper
• Dopamine receptor interactions: some implications for the treatment of Parkinson's disease.

  1992influential reference
• Ageing and Parkinson's disease: substantia nigra regional selectivity.

  1991cited by this paper
• The Importance of Graft Placement and Task Complexity for Transplant‐Induced Recovery of Simple and Complex Sensorimotor Deficits in Dopamine Denervated Rats

  1990cited by this paper
• 'Disengage' sensorimotor deficit following apparent recovery from unilateral dopamine depletion.

  1988cited by this paper
• Rate of cell death in parkinsonism indicates active neuropathological process

  1988cited by this paper
• Blindsight: A case study and implications

  1987influential reference
• The Rat Brain in Stereotaxic Coordinates

  1983influential reference
• Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites.

  1983cited by this paper
• Dendritic release of dopamine in the substantia nigra

  1981influential reference
• Time course of nigrostriatal degeneration in parkinson's disease

  1976cited by this paper
• Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

  1970cited by this paper

• Motor learning is regulated by postnatal GDNF levels in Purkinje cells.

  2025cites this paper
• Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease

  2025cites this paper
• Fundamental Research On and Practical Application Of GDNF as a Neuroprotective Agent in Neurodegenerative Diseases

  2025cites this paper
• Supramolecular nanostructure mimics GDNF trophic effects in vitro on human dopaminergic neurons

  2025cites this paper
• NLX-112 is anti-inflammatory, upregulates GDNF and is neuroprotective against MPTP-induced nigrostriatal dopaminergic degeneration in mice

  2025cites this paper
• GDNF reduces fibril-induced early-stage alpha-synuclein pathology after delivery of 20S proteasome inhibitor lactacystin.

  2025cites this paper
• Motor learning is regulated by GDNF levels in postnatal cerebellar Purkinje cells

  2024cites this paper
• Sleeping Beauty transposon system for GDNF overexpression of entrapped stem cells in fibrin hydrogel in a rat model of Parkinson’s disease

  2023cites this paper
• Architecture and regulation of a GDNF-GFRα1 synaptic adhesion assembly

  2023cites this paper
• Plasticity of Response Properties of Mouse Visual Cortex Neurons Induced by Optogenetic Tetanization In Vivo

  2023cites this paper
• Combined cell-based therapy strategies for the treatment of Parkinson’s disease: focus on mesenchymal stromal cells

  2022cites this paper
• Understanding the Potential of Genome Editing in Parkinson’s Disease

  2021cites this paper
• Mechanistic Insight from Preclinical Models of Parkinson’s Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy

  2021cites this paper
• Neuroinductive properties of mGDNF depend on the producer, E. Coli or human cells

  2021cites this paper
• Rat Models of Vocal Deficits in Parkinson’s Disease

  2021cites this paper
• Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats

  2021cites this paper
• GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop

  2020cites this paper
• The Effects of Deep Brain Stimulation of the Subthalamic Nucleus on Vascular Endothelial Growth Factor, Brain-Derived Neurotrophic Factor, and Glial Cell Line-Derived Neurotrophic Factor in a Rat Model of Parkinson’s Disease

  2020cites this paper
• Quantitative proteomic profiling of the rat substantia nigra places glial fibrillary acidic protein at the hub of proteins dysregulated during aging: Implications for idiopathic Parkinson's disease

  2020cites this paper
• What and How Can Physical Activity Prevention Function on Parkinson's Disease?

  2020cites this paper
• Botulinum Neurotoxin-A Injected Intrastriatally into Hemiparkinsonian Rats Improves the Initiation Time for Left and Right Forelimbs in Both Forehand and Backhand Directions

  2019cites this paper
• Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and Injury

  2019cites this paper
• Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson’s Disease Via Astrocytic GDNF

  2019cites this paper
• A Microfluidic Platform to Investigate the Mechanism by which GDNF Overexpression in Schwann Cells Causes Neuronal Axon Entrapment

  2019cites this paper
• Title Fibrin as a scaffold for delivery of GDNF overexpressing stemcells to the adult rat brain

  2019cites this paper
• Trophic factors for Parkinson's disease: Where are we and where do we go from here?

  2019cites this paper
• Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson’s disease

  2019cites this paper
• Therapeutic efficacy of glial cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo organotypic brain slice Parkinson's disease models.

  2019cites this paper
• Neurotoxins as Preclinical Models for Parkinson’s Disease

  2018cites this paper
• Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease

  2018cites this paper
• Title The potential of neurotrophic factors for the treatment of Parkinson ' s disease

  2018cites this paper
• Chapter 14 Cell-Based Therapies for Parkinson ’ s Disease : Preclinical and Clinical Perspectives

  2018cites this paper
• Serum glial cell line-derived neurotrophic factor levels and impulsivity in heroin addiction: a cross-sectional, case-control study of 129 heroin addicts

  2017cites this paper
• Role of Neurotrophic Factors in Parkinson's Disease.

  2017cites this paper
• Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson’s Disease Differently Affects Behavior

  2017cites this paper
• Biology of GDNF and its receptors - Relevance for disorders of the central nervous system.

  2017cites this paper
• Investigating chondroitin sulphate proteoglycans as a therapeutic target for Parkinson's disease

  2017cites this paper
• Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson’s Disease

  2016cites this paper
• Why We Cannot Translate Successful Results to New Therapies in Parkinson’s Disease

  2016cites this paper
• Admixing of MPTP-Resistant and Susceptible Mice Strains Augments Nigrostriatal Neuronal Correlates to Resist MPTP-Induced Neurodegeneration

  2016cites this paper
• Cell-Based Therapies for Parkinson’s Disease: Preclinical and Clinical Perspectives

  2016cites this paper
• Retrograde transport of neurotrophic factor signaling: implications in neuronal development and pathogenesis.

  2016cites this paper
• Nogo-A Neutralization Improves Graft Function in a Rat Model of Parkinson’s Disease

  2016cites this paper
• Dopamine is produced in the rat spinal cord and regulates micturition reflex after spinal cord injury.

  2016cites this paper
• Fibrin As a Scaffold for Delivery of GDNF Overexpressing Stem Cells to the Adult Rat Brain.

  2015cites this paper
• Melatonin enhances L‐DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced parkinsonism in mice

  2015cites this paper
• Trophic factors for Parkinson's disease: To live or let die

  2015cites this paper
• Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system.

  2015cites this paper
• GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease

  2015cites this paper
• Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease

  2015cites this paper
• Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease

  2015cites this paper
• Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.

  2014cites this paper
• Lentivirus-mediated delivery of sonic hedgehog into the striatum stimulates neuroregeneration in a rat model of Parkinson disease

  2014cites this paper
• The restorative effect of intramuscular injection of tetanus toxin C-fragment in hemiparkinsonian rats.

  2014cites this paper
• Time course of dopamine neuron loss and glial response in the 6‐OHDA striatal mouse model of Parkinson's disease

  2014cites this paper
• Melatonin’s Beneficial Effects on Dopaminergic Neurons in the Rat Model of Parkinson’s Disease

  2014cites this paper
• Effect of glial cell line‐derived neurotrophic factor on behavior and key members of the brain serotonin system in mouse strains genetically predisposed to behavioral disorders

  2013cites this paper
• The reduction in immunogenicity of neurotrophin overexpressing stem cells after intra-striatal transplantation by encapsulation in an in situ gelling collagen hydrogel.

  2013cites this paper
• Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).

  2013cites this paper
• A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function.

  2013cites this paper
• Intranasal Delivery of pGDNF Nanoparticles for Parkinson's Disease

  2013cites this paper
• GDNF, NGF and BDNF as therapeutic options for neurodegeneration.

  2013cites this paper
• Can We Teach Old Dogs New Tricks? Neuroprotective Cell Therapy in Alzheimer's and Parkinson's Disease

  2013cites this paper
• Restorative strategies for the dopaminergic nigrostriatal projection pathway.

  2013cites this paper
• Trophic Factor Gene Therapy for Parkinson's Disease

  2013cites this paper
• ROLE OF GDNF AND ITS CROSS-TALK WITH OTHER GROWTH FACTORS IN THE DOPAMINERGIC SYSTEM

  2012cites this paper
• Novel neurotrophic treatments in rats and toxin sensitivity of genetically modified mice in the unilateral 6 OHDA model of Parkinson's disease

  2012cites this paper
• The C-terminal domain of the heavy chain of tetanus toxin given by intramuscular injection causes neuroprotection and improves the motor behavior in rats treated with 6-hydroxydopamine.

  2012cites this paper
• Protective effect of methanolic extract of Garcinia indica fruits in 6-OHDA rat model of Parkinson's disease

  2012cites this paper
• Neurotrophic factors and neurodegenerative diseases: a delivery issue.

  2012cites this paper
• Cografting of carotid body cells improves the long-term survival, fiber outgrowth and functional effects of grafted dopaminergic neurons.

  2012cites this paper
• A new alternative NF-κB pathway mediated the neuroprotection of GDNF on 6-OHDA-induced DA neurons neurotoxicity.

  2012cites this paper
• Short- and long-term unilateral 6-hydroxydopamine lesions in rats show different changes in characteristics of spontaneous firing of substantia nigra pars reticulata neurons

  2012cites this paper
• Lentiviral Vector-Mediated Gene Transfer and RNA Silencing Technology in Neuronal Dysfunctions

  2011cites this paper
• Dopaminergic Neurons Derived from Human Embryonic Stem Cell Derived Neural Progenitors: Biological Relevance and Application

  2011cites this paper
• An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats

  2011cites this paper
• Neurotrophic factors for the treatment of Parkinson's disease.

  2011cites this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cites this paper
• Kerttu Koskenniemi Proteomic Characterization of Probiotic Lactobacillus rhamnosus GG 3 / 2012 Laura Lahti FGF Signaling in Neurogenesis and Patterning of the Developing Midbrain and Anterior Hindbrain

  2011cites this paper
• The potential of neurotrophic factors for the treatment of Parkinson's disease

  2011cites this paper
• Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

  2010cites this paper
• Dopamine Neuron Stimulating Actions of a GDNF Propeptide

  2010cites this paper
• Expressions and possible roles of GDNF receptors in the developing dopaminergic neurons.

  2010cites this paper
• Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain.

  2010cites this paper
• Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease

  2009cites this paper
• Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease

  2009cites this paper
• Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons.

  2009cites this paper
• Effects of calpain inhibition on dopaminergic markers and motor function following intrastriatal 6-hydroxydopamine administration in rats.

  2009cites this paper
• Role of Ret Signaling in the Regulation of the Nigrostriatal Dopaminergic System in Mice

  2009cites this paper
• Pattern of long‐term sensorimotor recovery following intrastriatal and ‐accumbens DA micrografts in a rat model of Parkinson's disease

  2009cites this paper
• NOVEL CDNF/MANF PROTEIN FAMILY: MOLECULAR STRUCTURE, EXPRESSION AND NEUROTROPHIC ACTIVITY

  2009cites this paper
• Walking pattern analysis after unilateral 6-OHDA lesion and transplantation of foetal dopaminergic progenitor cells in rats.

  2009cites this paper
• The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.

  2009cites this paper
• Both pre- and post-lesion experiential therapy is beneficial in 6-hydroxydopamine dopamine-depleted female rats.

  2009cites this paper
• Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease

  2009cites this paper
• GDNF therapy for Parkinson’s disease

  2008cites this paper
• Applications of lentiviral vectors for biology and gene therapy of neurological disorders.

  2008cites this paper
• SK channel function regulates the dopamine phenotype of neurons in the substantia nigra pars compacta.

  2008cites this paper
• Maternal separation exaggerates the toxic effects of 6-hydroxydopamine in rats: Implications for neurodegenerative disorders

  2008cites this paper
• Activation of the extracellular signal‐regulated kinases 1 and 2 by glial cell line‐derived neurotrophic factor and its relation to neuroprotection in a mouse model of Parkinson's disease

  2008cites this paper